

Appendix 4E

Preliminary Final Report

1. Company details

Name of entity

Pro Medicus Limited

ABN or equivalent
company reference

25 006 194 752

Financial year ended
('current period')

30 June 2011

Financial year ended
('previous period')

30 June 2010

2. Results for announcement to the market

ASX Listing Rules Ref		2011 A\$'000
2.1	Revenue % change up/(down) of revenue from ordinary activities from the previous corresponding period.	14,070 Down 27.7%
2.2	Profit after tax attributable to members % change up/(down) of Profit/(Loss) from ordinary activities after tax attributable to members from the previous corresponding period.	503 Down 87.2%
2.3	Net Profit for the period attributable to members % change up/(down) of Net Profit/(Loss) for the period attributable to members from the previous corresponding period.	503 Down 87.2%

2.4	Dividends (distributions)	Amount per security	Fully Franked amount per security
	Franked dividend amount per security		
	Final Dividend	-	-
	Interim dividend	-	-
2.5	Record date for Final dividends	N/A	
	Payment date for Final dividends	N/A	

2.6	Australia The group employs 25 people in Australia who undertake research and development of Pro Medicus products as well as sales and service/support functions. The group's Australian revenue declined over the period by 41.1% due to slower than anticipated sales of the Visage 7.0 products and well as a decline in new Radiology Information System (RIS) sales due to the delays in bringing the company's new RIS technology platform to market. Promedius.net, the company's e-health offering, continued to hold its strong market position recording revenue of \$1.89 million despite increasing competition. North America The group employs 10 people in North America to fulfil the sales marketing and professional services roles. Revenue from North America declined by 14.2% compared to the previous year of which 9% was attributable to currency changes. The company has made a number of changes in the group's US operations during the past year including a significant decrease in overall running costs and changes to management in the 2nd half of the financial year. The company believes these changes will have a positive impact on the performance of the North American division in the coming years. Europe Pro Medicus established a presence in Europe with the acquisition of Visage Imaging GmbH in late January 2009. The group has 41 employees in its Berlin office who undertake research and development of Visage Imaging products worldwide as well as sales, marketing and service/support functions for the group's European operations. Financials Full year revenue, declined from \$19.46 million to \$14.07 million, a decrease of 27.7%. Net margin as defined by profit before tax to revenue from operating activities decreased from 32.3% to 5.0% reflecting the decrease in sales of new products and higher development costs. Profit after tax for the period was \$0.50 million a decrease of 87.2% from the previous year in what was a difficult year for the industry. The result was impacted by a decrease in new sales, a number of one-off termination payments and significant impact from foreign currency exchange rates. Shareholder Returns The directors are confident that the holdings of reserve cash is sufficient to underpin the development and expansion needs of the company as the business looks to increase its penetration of existing markets and new product development. The company has maintained cash holdings although the return on net assets and equity has decreased as a result of the acquisition of the Visage Imaging business and lower profitability than prior years.
3.	Statement of Comprehensive Income Please refer to the Statement of Comprehensive Income in the attached Financial Statements.
4.	Statement of Financial Position Please refer to the Statement of Financial Position in the attached Financial Statements.
5.	Statement of cash flows Please refer to the Statement of cash flows in the attached Financial Statements.

6.	Details of Dividends <table><thead><tr><th></th><th>2011 \$'000</th><th>2010 \$'000</th></tr></thead><tbody><tr><td>Final Dividend</td><td></td><td></td></tr><tr><td>No Final Dividend (2010: 2.0) per share will be paid.</td><td>Nil</td><td>\$2,005.6</td></tr><tr><td>Current Year Interim</td><td></td><td></td></tr><tr><td>No interim dividend was paid during 2010-11 (2010: Nil)</td><td>-</td><td>-</td></tr><tr><td>No foreign sourced dividend or distribution is included in either the interim or final dividends.</td><td></td><td></td></tr></tbody></table>		2011 \$'000	2010 \$'000	Final Dividend			No Final Dividend (2010: 2.0) per share will be paid.	Nil	\$2,005.6	Current Year Interim			No interim dividend was paid during 2010-11 (2010: Nil)	-	-	No foreign sourced dividend or distribution is included in either the interim or final dividends.		
	2011 \$'000	2010 \$'000																	
Final Dividend																			
No Final Dividend (2010: 2.0) per share will be paid.	Nil	\$2,005.6																	
Current Year Interim																			
No interim dividend was paid during 2010-11 (2010: Nil)	-	-																	
No foreign sourced dividend or distribution is included in either the interim or final dividends.																			
7.	Dividend or Distribution reinvestment plans There are no dividend or distribution reinvestment plans in operation.																		
8.	Statement of Retained Earnings Please refer to Statement of Changes in Equity in the attached Financial Statements.																		
9.	<table><thead><tr><th>Net Tangible Assets per security</th><th>2011</th><th>2010</th></tr></thead><tbody><tr><td>Net Tangible Assets per security</td><td>\$0.02</td><td>\$0.07</td></tr></tbody></table>	Net Tangible Assets per security	2011	2010	Net Tangible Assets per security	\$0.02	\$0.07												
Net Tangible Assets per security	2011	2010																	
Net Tangible Assets per security	\$0.02	\$0.07																	
10.	Details of entities over which control has been gained or lost during the period There are no entities over which control has been gained or lost during the period																		
11.	Associates and joint venture entities There are no associates or joint venture entities																		
12.	Other significant information needed by an investor to make an informed assessment of the entity’s financial performance and financial position. Please refer to section 2.6																		
13.	Foreign Entity accounting standards Australian Accounting Standards & International Financial Reporting Standards																		

14.	Commentary on results for the period. The earnings per security and the nature of any dilution aspects. Please refer to Note 8 of the attached Financial Statements. Returns to shareholders including distributions and buy backs. Please refer to Note 9 of the attached Financial Statements. Significant features of operating performance. Please refer to section 2.6. The results of segments that are significant to an understanding of the business. Please refer to Note 5 of the attached Financial Statements. Discussion of trends in performance. Please refer to section 2.6.
15.	Audit Statement This report is based on accounts to which one of the following applies. (Tick one) ☒ The *accounts have been audited. ☐ The *accounts have been subject to review. ☐ The *accounts are in the process of being audited. ☐ The *accounts have <i>not</i> yet been audited or reviewed.

Sign here:

Date: 26 August 2011



Print name: Sam Hupert
Chief Executive Officer